ClinicalTrials.gg
CompletedNCT02085252Updated Jun 28, 2019Results posted

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

A Phase 3 interventional study of Leuprorelin and Bicalutamide in Prostate Cancer, sponsored by Takeda. Completed at 2 sites in France. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-06-28.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
27th of 69
116 · median 77
Started
2013
with 2 others
Phase 3
26 of 70
3 open now
Registered
33rd of 70
by date
Lead sponsor
3 of 70
Takeda

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 27th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2013, is one of 26 in phase 3, and was the 33rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 50 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess two treatment strategies (leuprorelin treatment and active surveillance without androgen deprivation) for indolent prostate cancer and to compare their therapeutic benefit for management of patients with low-risk, localized prostate cancer.

Read the detailed description

The drug being tested in this study is called leuprorelin. Leuprorelin is being tested to treat people who have prostate cancer. Study assessments will include adverse events, prostatic-specific antigen (PSA) levels, and prostate biopsies.

The study will enroll approximately 120 patients. Participants will be randomly assigned (by chance, like flipping a coin) to a treatment group that will receive leuprorelin 11.25 mg (as one injection) or to an untreated observation group. Patients in the leuprorelin group will also receive bicalutamide 50 mg, a non-steroidal antiandrogen, once daily for 15 days to prevent a flare-up.

This multi-center trial will be conducted in France. The overall time to participate in this study is 12 months. After the screening visit, participants will make 6 visits to the clinic.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is an out-patient 50 to 80 years old.
  2. Has read, understood, signed and dated the .
  3. Has indolent prostate cancer defined by:

    • Clinical Stage T1c or T2a.
    • cores of which at least 12 reveal the presence of positive cores and the absence of cores with tumor length > 3 mm.
    • Absence of Grade 4 cells (Gleason \<7).
    • Prostate specific antigen (PSA) levels \<10 ng/ml.
  4. Has a > 5 years.
  5. Has accepted the principle of active surveillance.
  6. Is willing to participate in the study for a minimum of fifteen months.

Exclusion criteria

Exclusion Criteria:

  1. Has prior androgen deprivation including a 5-alpha reductase inhibitor (finasteride or dutasteride) within the last 6 months.
  2. Has psychological failure related to prostate cancer therapy.
  3. Has any active disorder likely to affect the conduct of the study or the patient's prognosis during the study.
  4. Has a mental deficiency or any other reason that may hinder the understanding or strict application of the protocol.
  5. Is under judicial protection, tutorship or curatorship.
  6. Is unlikely to attend control visits.
  7. Is currently enrolled in an study or has participated in another investigational study within the last 3 months.
  8. Has an allergy or to any components of leuprorelin (Enantone LP) 11.25 mg or Casodex® 50 mg.
  9. Has a medical history of severely impaired hepatic function linked to bicalutamide or a pathological cause.
  10. Has testosterone level \< 0.5 ng/ml.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Leuprorelin 11.25 mg

    Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.

    Drug: Leuprorelin · Drug: Bicalutamide

  • No intervention
    Active surveillance

    Active surveillance is close medical monitoring of prostate cancer for any changes.

Interventions

  • Solution for injection

    Also known as: Enantone ®

  • Bicalutamide tablets

    Also known as: Casodex ®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Negative Biopsies at Month 12

    Staging biopsy of at least 12 cores were sampled and analyzed according to a centralized biopsy procedure which confirm the results of the first biopsy \[presence of positive cores, the absence of core with tumor length \> 3 millimeters (mm), and absence Grade 4 cells (Gleason score \< 7)\]. The Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.

    Time frame: Month 12

Secondary outcomes

  1. Number of Participants With Gleason Score ≥ 7

    Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.

    Time frame: Month 12

  2. Change From Baseline in the International Prostate Symptom Score (I-PSS) Total Symptom (S) Score

    The I-PSS is an 8-question tool used to measure prostate symptoms (≤7: mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic). The first 7 symptom questions answered on a scale of 0 (never) to 5 (almost always) are used to determine the I-PSS Total S Score for a total possible score of 0 to 35. The 8th question is quality of life and is not reported here. A negative change from baseline indicates improvement. An Analysis of Covariance (ANCOVA) model fitted with baseline I-PSS total score and age as covariates was used for analysis.

    Time frame: Baseline and Months 3, 6, 9 and 12

  3. Prostatic Volume as a Measure of Tumor Radiologic Progression Using Dynamic Magnetic Resonance Imaging (MRI)

    MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to calculate the prostatic volume in cubic millimeters (mm\^3).

    Time frame: Baseline and Month 12

  4. Highest Diameter of the Lesion as a Measure of Tumor Radiologic Progression Using Dynamic MRI

    MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to determine the diameter of the lesions in millimeters (mm).

    Time frame: Baseline and Month 12

  5. Change From Baseline in Prostate-specific Antigen (PSA) Levels

    Blood was collected and sent to a central laboratory for analysis of PSA reported in milligrams/milliliter (mg/mL). A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline PSA Level and age as covariates was used for analyses.

    Time frame: Baseline and Months 3, 6, 9 and 12

  6. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score

    The HADS is a 14-item scale that measures anxiety (7-items) and depression (7-items) over the previous week. Each question is answered on a scale of 0 (best) to 3 (worst) for a total possible score of 0 to 42, with higher scores indicating more anxiety and depression. A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline HADS score and age as covariates was used for analyses.

    Time frame: Baseline and Months 3, 6, 9 and 12

  7. Change From Baseline in the International Index of Erectile Function (IIEF-5) Questionnaire Score

    The IIEF-5, a 5 question patient completed questionnaire, is a measure of erectile dysfunction over the past 6 months. Each question is answered on a scale of 1 (worst) to 5 (best). Total score ranges from 5 to 25 with higher scores indicating better function (5-7: severe; 8-11: moderate; 12-16: mild to moderate;17-21: mild; 22-25: none). A positive change from baseline indicates improvement. A negative change from baseline indicates a worsening. An ANCOVA model fitted with baseline IIEF-5 score and age as covariates was used for analyses.

    Time frame: Baseline and Months 3, 6, 9 and 12

07

Results

Posted Apr 16, 2019

Participant flow

Participants took part in the study at 22 investigative sites in France from 03 June 2013 to 08 November 2016.

Participant flow — Overall Study
MilestoneLeuprorelin 11.25 mgActive Surveillance
Started5857
Completed5753
Not completed14
Withdrew: Withdrawal of consent10
Withdrew: Adverse event01
Withdrew: Discontinuation due to patient decision01
Withdrew: Reason not specified01
Withdrew: Reason unknown01

Outcome measures

PrimaryNumber of Participants With Negative Biopsies at Month 12

Staging biopsy of at least 12 cores were sampled and analyzed according to a centralized biopsy procedure which confirm the results of the first biopsy \[presence of positive cores, the absence of core with tumor length \> 3 millimeters (mm), and absence Grade 4 cells (Gleason score \< 7)\]. The Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.

Time frame:
Month 12
Reported as:
Count of participants · Participants
Number of Participants With Negative Biopsies at Month 12
ParticipantsLeuprorelin 11.25 mgActive Surveillance
Number of Participants With Negative Biopsies at Month 122817
Statistical analysis
  • Leuprorelin 11.25 mg vs Active Surveillance · Chi-squared · p = 0.0318 (A 2-sided significance level of 5% was used. There was no adjustment for multiple comparisons.)
SecondaryNumber of Participants With Gleason Score ≥ 7

Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.

Time frame:
Month 12
Reported as:
Count of participants · Participants
Number of Participants With Gleason Score ≥ 7
ParticipantsLeuprorelin 11.25 mgActive Surveillance
Number of Participants With Gleason Score ≥ 713
SecondaryChange From Baseline in the International Prostate Symptom Score (I-PSS) Total Symptom (S) Score

The I-PSS is an 8-question tool used to measure prostate symptoms (≤7: mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic). The first 7 symptom questions answered on a scale of 0 (never) to 5 (almost always) are used to determine the I-PSS Total S Score for a total possible score of 0 to 35. The 8th question is quality of life and is not reported here. A negative change from baseline indicates improvement. An Analysis of Covariance (ANCOVA) model fitted with baseline I-PSS total score and age as covariates was used for analysis.

Time frame:
Baseline and Months 3, 6, 9 and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in the International Prostate Symptom Score (I-PSS) Total Symptom (S) Score
score on a scaleLeuprorelin 11.25 mgActive Surveillance
Change at Month 30.37 (-0.70 to 1.43)1.03 (-0.05 to 2.11)
Change at Month 6-0.38 (-1.27 to 0.51)0.32 (-0.59 to 1.24)
Change at Month 9-1.13 (-1.97 to -0.28)0.64 (-0.23 to 1.52)
Change at Month 12-0.48 (-1.52 to 0.56)0.93 (-0.14 to 2.01)
SecondaryProstatic Volume as a Measure of Tumor Radiologic Progression Using Dynamic Magnetic Resonance Imaging (MRI)

MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to calculate the prostatic volume in cubic millimeters (mm\^3).

Time frame:
Baseline and Month 12
Reported as:
Mean · mm^3
Prostatic Volume as a Measure of Tumor Radiologic Progression Using Dynamic Magnetic Resonance Imaging (MRI)
mm^3Leuprorelin 11.25 mgActive Surveillance
Baseline48.48 ± 25.0949.44 ± 25.88
Month 1251.47 ± 28.1548.33 ± 20.18
SecondaryHighest Diameter of the Lesion as a Measure of Tumor Radiologic Progression Using Dynamic MRI

MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to determine the diameter of the lesions in millimeters (mm).

Time frame:
Baseline and Month 12
Reported as:
Mean · mm
Highest Diameter of the Lesion as a Measure of Tumor Radiologic Progression Using Dynamic MRI
mmLeuprorelin 11.25 mgActive Surveillance
Baseline6.39 ± 2.807.78 ± 2.02
Month 126.25 ± 3.627.69 ± 2.56
SecondaryChange From Baseline in Prostate-specific Antigen (PSA) Levels

Blood was collected and sent to a central laboratory for analysis of PSA reported in milligrams/milliliter (mg/mL). A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline PSA Level and age as covariates was used for analyses.

Time frame:
Baseline and Months 3, 6, 9 and 12
Reported as:
Least squares mean · mg/mL
Change From Baseline in Prostate-specific Antigen (PSA) Levels
mg/mLLeuprorelin 11.25 mgActive Surveillance
Change at Month 3-4.61 (-5.07 to -4.15)0.22 (-0.25 to 0.70)
Change at Month 6-3.27 (-3.95 to -2.59)0.85 (0.15 to 1.55)
Change at Month 9-1.46 (-1.96 to -0.95)0.71 (0.20 to 1.21)
Change at Month 120.17 (-0.69 to 1.04)0.76 (-0.13 to 1.66)
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Score

The HADS is a 14-item scale that measures anxiety (7-items) and depression (7-items) over the previous week. Each question is answered on a scale of 0 (best) to 3 (worst) for a total possible score of 0 to 42, with higher scores indicating more anxiety and depression. A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline HADS score and age as covariates was used for analyses.

Time frame:
Baseline and Months 3, 6, 9 and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score
score on a scaleLeuprorelin 11.25 mgActive Surveillance
Change at Month 3-0.83 (-1.76 to 0.11)-1.20 (-2.17 to -0.24)
Change at Month 6-1.44 (-2.53 to -0.35)-1.58 (-2.69 to -0.47)
Change at Month 9-2.06 (-3.21 to -0.91)-1.76 (-2.95 to -0.56)
Change at Month 12-1.87 (-2.98 to -0.76)-1.95 (-3.09 to -0.80)
SecondaryChange From Baseline in the International Index of Erectile Function (IIEF-5) Questionnaire Score

The IIEF-5, a 5 question patient completed questionnaire, is a measure of erectile dysfunction over the past 6 months. Each question is answered on a scale of 1 (worst) to 5 (best). Total score ranges from 5 to 25 with higher scores indicating better function (5-7: severe; 8-11: moderate; 12-16: mild to moderate;17-21: mild; 22-25: none). A positive change from baseline indicates improvement. A negative change from baseline indicates a worsening. An ANCOVA model fitted with baseline IIEF-5 score and age as covariates was used for analyses.

Time frame:
Baseline and Months 3, 6, 9 and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in the International Index of Erectile Function (IIEF-5) Questionnaire Score
score on a scaleLeuprorelin 11.25 mgActive Surveillance
Change at Month 3-7.40 (-9.02 to -5.78)0.00 (-1.65 to 1.65)
Change at Month 6-5.87 (-7.52 to -4.22)0.01 (-1.69 to 1.71)
Change at Month 9-1.94 (-3.20 to -0.67)-0.38 (-1.69 to 0.94)
Change at Month 12-1.68 (-3.11 to -0.24)-0.02 (-1.49 to 1.46)

Adverse events

Collected over First dose of study drug to the End of Study Visit (Up to 12 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprorelin 11.25 mg—4/58 (6.9%)40/58 (69%)
Active Surveillance—3/57 (5.3%)11/57 (19.3%)
Most frequent serious events
Most frequent serious events
EventLeuprorelin 11.25 mgActive Surveillance
ErysipelasInfections and infestations0/581/57
Urinary tract disorderRenal and urinary disorders0/581/57
Pancreatic neoplasmGastrointestinal disorders0/581/57
Atrial flutterCardiac disorders1/580/57
FatigueVascular disorders1/580/57
DizzinessVascular disorders1/580/57
DeafnessEar and labyrinth disorders1/580/57
Most frequent other events
Showing 10 of 12
Most frequent other events
EventLeuprorelin 11.25 mgActive Surveillance
Hot flushReproductive system and breast disorders17/580/57
FlushingVascular disorders9/580/57
Erectile dysfunctionPsychiatric disorders7/582/57
Libido decreasedReproductive system and breast disorders6/580/57
Hot flushVascular disorders6/580/57
Back painMusculoskeletal and connective tissue disorders2/584/57
FatigueGeneral disorders4/580/57
DysuriaRenal and urinary disorders4/582/57
HypertensionVascular disorders1/583/57
BronchitisInfections and infestations3/582/57

Baseline characteristics

Full Analysis Set included all participants with prostate cancer who signed informed consent and were randomised.

Age, Continuous
Age, Continuous(years)Leuprorelin 11.25 mgActive SurveillanceTotal
Mean66.22 ± 5.7663.60 ± 5.5664.92 ± 5.79
Sex: Female, Male
Sex: Female, Male(Participants)Leuprorelin 11.25 mgActive SurveillanceTotal
Female000
Male5857115
Region of Enrollment
Region of Enrollment(Participants)Leuprorelin 11.25 mgActive SurveillanceTotal
France5857115
Height
Height(centimeters (cm))Leuprorelin 11.25 mgActive SurveillanceTotal
Mean171.85 ± 6.55173.69 ± 8.08172.77 ± 7.38
08

Study locations

2 sites
  • Tenon Hospital Paris France
    Paris, 75020, France
  • Ouzid, Paris La Défense,
    Paris, 92977, France
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Nov 2016, 41 months.

Results were first posted in Apr 2019, 2 years 5 months after primary completion. A results delay was requested in Feb 2017.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 41 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2013
First posted
Mar 12, 2014
StartActual
Jun 3, 2013
Primary completionActual
Nov 8, 2016
CompletionActual
Nov 8, 2016
Results delay requested
Feb 2, 2017
Results first posted
Apr 16, 2019
Last update
Jun 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02085252
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 12, 2014
Start date
Jun 3, 2013
Primary completion
Nov 8, 2016
Completion
Nov 8, 2016
Results posted
Apr 16, 2019
Last update
Jun 28, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion